Sitagliptin Versus Insulin Dose Increase in Type 2 Diabetes on Insulin Treatment
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
It is well established that inhibition of dipeptidyl peptidase (DPP)-IV reduces glucose
levels and preserves pancreatic beta cell function in patients with type 2 diabetes. DPP-IV
inhibitors stimulate insulin secretion as well as insulin biosynthesis and inhibit glucagon
secretion from pancreas by increasing incretin (GLP-1) levels. Recent studies reported that
combination therapy with DPP-IV inhibitors and other oral antidiabetic medication have
additive or synergistic effects in lowering glycose level, preserving beta-cell mass and
function as well as enhancing insulin sensitivity. However, there have been few studies about
the glucose lowering effect of DPP-IV inhibitors in patients with type 2 diabetes on insulin
treatment.
The researchers hypothesized that DPP-IV inhibitor add-on therapy to insulin treatment may
have favorable effects on glucose control and endogenous insulin secretory function in type 2
diabetic patients. The researchers plan to compare between sitagliptin (DPP-IV inhibitor)
add-on therapy and insulin dose increase therapy in uncontrolled type 2 diabetes on insulin
treatment.